7-Aminocephalosporanic Acid (7-ACA) Market to Set $1,264.68 Mn

7-Aminocephalosporanic Acid (7-ACA) Market Size, Trends and Future Growth

The global 7-Aminocephalosporanic Acid (7-ACA) market was estimated at US$ 671.2 million in 2023 and is projected to grow to US$ 1,264.68 million by 2034, rising at a compound annual growth rate (CAGR) of 5.54% from 2024 to 2034. The demand for 7-ACA is high in the market because it is a core component for the synthesis of cephalosporin.

Unlock Infinite Advantages: Subscribe to Annual Membership

Market Overview

The fundamental chemical structure, or synthon, for the production of cephalosporin antibiotics and intermediates, is 7-ACA (7-aminocephalosporanic acid). β-lactam antibiotics, known as cephalosporins, are used to treat a variety of illnesses brought on by both gram-positive and gram-negative bacteria. The treatment of meningitis, pneumonia, skin and soft tissue infections, and other diseases has been proven to be effective with the five generations of cephalosporins. The 7-Aminocephalosporanic Acid (7-ACA) market is growing due to the growing number of infections globally.

7-Aminocephalosporanic Acid (7-ACA) Market Trends

• In June 2024, the World Health Organization (WHO) just published its most recent report on antibacterial agents—including antibiotics—that are being developed globally in preclinical and clinical stages. Even if there are now 97 antibacterial medicines in clinical trials as opposed to 80 in 2021, there is still a critical need for novel, cutting-edge treatments for severe infections to replace ones that are running out of steam from broad usage.
• In November 2023, beta-lactam antibiotics were first launched by Addii Biotech, a renowned third-party pharmaceutical producer based in India. A company with FDA-Ghana approval and WHO-GMP certification that demonstrates a cutting-edge approach to the production of pharmaceutical products, providing clients with beta-lactam products such as tablets, capsules, and dry syrups while also drawing interest from other services for its outsourcing.

Growing Infectious Diseases Promotes the Market’s Growth

7-ACA is used as a component for the production of various antibiotics. These antibiotics are used in the treatment of various infections such as strep throat, pneumonia, ear infections, skin or soft tissue infections, meningitis, UTIs, sinus infections, and gonorrhea. As the population grows, the number of cases of infectious diseases is estimated to grow significantly. With a large number of patients with infections, the demand for antibiotics is going to grow in the future, which will promote the 7-Aminocephalosporanic Acid (7-ACA) market.

For instance,

• 700,000 children die from pneumonia each year, making it the most common infectious illness.
• Over 2 million cases of pneumonia were reported to the CDC in the United States.
• From July to December 2022 and January to June 2023, gonorrhea infections rose sharply among women aged 20 to 24 in 15 EU/EEA countries; 73% and 89% more cases than anticipated were recorded in these periods.
• 150 million people worldwide are afflicted by the most prevalent infectious illness in the world, which has a high rate of morbidity and expensive treatment (repeated UTIs are thought to cost the US economy more than $5 billion annually). 

Environmental Concerns

The 7-Aminocephalosporanic Acid (7-ACA) market faces challenges due to the pollution generated during the production of 7-ACA. The process includes various steps during which a lot of pollution is generated. Better and more sustainable procedures are being developed to tackle this challenge. However, balancing between cost, efficiency, and sustainability can be challenging.

Regional Insights

North America Dominated the 7-Aminocephalosporanic Acid (7-ACA) market in 2023.

North America is a well-established region known for its technological advancements, advanced healthcare infrastructure, growing R&D in biotechnology and pharmaceutical industries, presence of major market players, and government investments. All these factors work in the favour of the market’s growth. The two major countries that contribute to the market’s growth are the U.S. and Canada.

The U.S. has an advanced healthcare system that ensures that all the resources are available for timely treatment. Another factor that is promoting the 7-Aminocephalosporanic Acid (7-ACA) market’s growth is the growing number of various infectious diseases.

For instance,

• The cases of gonorrhea rose from 583,405 in 2018 to 648,056.
• Female UTIs are quite prevalent; in the U.S., 25–40% of women between the ages of 20 and 40 have experienced a UTI. Over 6 million patient visits to physicians are related to UTIs in the US each year; 20% of these visits occur in emergency departments. Over 626,000 hospital admissions for complex UTIs occur in the US each year, accounting for 1.8% of all hospitalizations.
• A serious health issue is sinus infection, sometimes referred to as sinusitis. Thirty-one million Americans suffer from it. Every year, over $1 billion is spent by Americans on over-the-counter drugs to treat it. A total of $150 million in prescription drug costs and 16 million doctor visits are attributed to sinus infections. 
• In November 2023, new guidelines that instantly explain the US Food and Drug Administration's (FDA) enforcement policy for the production of certain oral antibiotic suspension products that contain beta-lactams have been issued.

Asia Pacific is expected to grow at the fastest rate during the forecast period.

The 7-Aminocephalosporanic Acid (7-ACA) market is growing in the region due to the growing number of cases of infectious diseases. Apart from this, governments, public and private organizations, research institutions, and others are making efforts to tackle the issue. The major countries that contribute to the market’s growth are China, India, Japan, and South Korea. Among these countries, China and India hold the second and third largest share of the pharmaceutical industry, respectively. It indicates that the production of antibiotics is done on a large scale for usage and export.

An estimated 134 million Indians are thought to be affected by chronic sinusitis, which can cause severe headaches, fever, nasal congestion, and blockage, among other symptoms. That exceeds the number of people living in Japan. Of the 1 393 400 000 persons in India, an estimated 57 251 328 (4.1%) have a severe fungal condition.

Segmental Insights

By product, the enzymatic hydrolysis segment dominated the 7-Aminocephalosporanic Acid (7-ACA) market in 2023. It is the process that produces 7-ACA the most frequently. The immobilized enzymes utilized in the method have the benefit of being readily recoverable from the reaction media and reusable several times due to their insolubility; this is a critical and essential requirement for an industrial process. The ability to easily recover the enzyme from the reaction mass not only makes it easier to recover the finished product but also allows the reaction solution from the first stage to be used directly in the second stage, which is another significant industrial benefit of the current invention. 

By application, the ceftriaxone segment held the largest share of the 7-Aminocephalosporanic Acid (7-ACA) market in 2023. An antibiotic called ceftriaxone is administered intravenously by a medical professional at a hospital or clinic. It is a third-generation antibiotic made from 7-ACA cephalosporins. Because ceftriaxone is so well-liked in hospitals and clinics for infectious disorders, it exhibits good efficacy against the majority of gram-negative bacteria.

Recent Developments

• In March 2024, Pfizer Inc. declared that EMBLAVEO® (aztreonam-avibactam) should be granted a marketing authorization after the EMA's CHMP issued a favorable view. In the event that it is authorized, EMBLAVEO® would be the first combination of β-lactam/β-lactamase inhibitors used to treat severe bacterial infections.
• In December 2023, the debut of FetrojaTM was announced by Shionogi & Co., Ltd. A novel siderophore cephalosporin antibiotic is called Fetroja. The Ministry of Health, Labour, and Welfare approved its marketing and manufacture for a range of illnesses.
• In July 2023, the Chennai-based pharmaceutical manufacturer Orchid Pharma said that, as part of the production-linked incentive (PLI) program, it has joined forces with a top global biotechnology business to transfer knowledge for the fermentation-based "7ACA project."

Top Companies in the 7-Aminocephalosporanic Acid (7-ACA) Market

• CSPC
• Nectar Lifesciences
• INNER MONGOLIA
• Joincare
• Dragon Pharma
• Fujian Fukang
• Sinopharm Weiqida Pharma
• Shandong Lukang
• Yili Chuangning Biotechnology
• Harbin Pharmaceutical
• CordenPharma
• NCPC

Segments Covered in the Report

By Product

• Enzymatic Hydrolysis
• Chemical Cracking

By Application

• Ceftriaxone
• Cefazolin
• Ceftazidime
• Cefotaxime

By Region

• North America
  
  • U.S.
  • Canada
• Asia Pacific 
  
  • China
  • Japan
  • India
  • South Korea
  • Thailand
• Europe 
  
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Sweden
  • Denmark
  • Norway
• Latin America 
  
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa (MEA) 
  
  • South Africa
  • UAE
  • Saudi Arabia
  • Kuwait